drugset / Trial / NCT03267329

Duowell® vs. Telmisartan Monotherapy in Mild Dyslipidemia Patients With Hypertension

NCT03267329

Phase 4 Completed 80 enrolled Yuhan Corporation
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is to evaluate effect and safety on central blood pressure with Duowell compared to telmisartan monotherapy in mild dyslipidemia patients with hypertension during 16 weeks.

Timeline

Start
2017-09-11
Primary completion
2020-09-02
Completion
2020-09-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosuvastatin Small molecule 10 mg
Subject Rosuvastatin Small molecule 20 mg
Comparator Telmisartan Other / unclassified 80 mg